We reiterate our HOLD rating on Ahold Delhaize but lower our target price from €36 to €35, as we reduce our top- and bottom-line forecasts on higher FX headwinds. We remain cautious on Ahold Delhaize USA's organic growth, noting the ongoing price investment programme while inflation starts to build, as highlighted by market leader Walmart in its 2Q release. Consensus continues to see flat underlying operating profit in the country (excl. FX), while we remain more cautious there. This leads us to...
Ahold Delhaize reported a solid set of 2Q25 results, with comparable sales growth of 3.4% in the US (css: +3.1%) and +4.9% in the EU (css: +3.8%) exceeding expectations. While group margins contracted by 20bps to 4.0%, this was well anticipated on the back of ongoing price investments in the US and the dilutive impact from the consolidation of Profi in the EU. As such, the underlying group EBIT of € 917m came in slightly ahead of expectations (css: € 908m, css: € 905m). Following the solid 2Q25,...
ABN AMRO: Better bottom line, mixed underlying, strong capital, SBB €250m. Ahold Delhaize: 2Q25 profitability beat thanks to insurance results. Coca-Cola Europacific Partners PLC: Fizzing along nicely. Kinepolis: July 2025 box office in US/Canada and France down, on strong comps. Vonovia: Good results, 5.6% guidance increase. UCB: Evenity continues to surprise to the upside. Zabka: Another miss on Adj. Net Income in 2Q25
Rdos. 2T'25 vs 2T'24: Ventas: 23.092 M euros (+3,3% vs +2,8% BS(e) y +2,7% consenso); EBIT: 917,0 M euros (-1,7% vs -2,9% BS(e) y -2,7% consenso); BDI: 548,0 M euros (+9,8% vs +14,4% BS(e) y +14,2% consenso). Rdos. 1S'25 vs 1S'24: Ventas: 46.368 M euros (+5,2% vs +4,9% BS(e) y +4,9% consenso); EBIT: 1.807 M euros (+0,7% vs +0,1% BS(e) y +0,2% consenso);
Rdos. 2T'25 vs 2T'24: Ventas: 19.826 M euros (-3,9% vs +1,9% BS(e) y +1,8% consenso); EBIT: 1.429 M euros (+5,8% vs -0,6% BS(e) y -1,7% consenso); BDI: 815,0 M euros (+9,5% vs -0,5% BS(e) y -1,6% consenso). Rdos. 1S'25 vs 1S'24: Ventas: 40.635 M euros (-0,6% vs +2,3% BS(e) y +2,3% consenso); EBIT: 2.799 M euros (+5,0% vs +1,8% BS(e) y +1,2% consenso); BDI: 1.601 M euros (+7,7% vs +2,6% BS(e) y +2,1% consenso).
NEWS SUMMARY: CELLNEX, NATURGY. Stock markets pause for a break European stock markets recovered after the strong corrections seen last Friday, fuelled by banks. Thus, in the STOXX 600 most sectors (16/20) ended with gains, led by Banks and Insurance vs. Pharma and Retail that were the worst performers. On the macro side, in the euro zone, August’s Sentix dropped significantly as opposed to expectations following the tariff agreement signed with the US to the worst level since April. In the US,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.